MPTP诱导小鼠肝脏帕金森病样病理变化研究

doi:10.19803/j.1672-8629.2021.04.02

摘要/Abstract

摘要： 目的研究1-甲基-4-苯基-1,2,3,6-四氢吡啶（1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, MPTP）诱导的帕金森病（Parkinson's disease, PD）小鼠模型中肝脏生理功能变化和病理改变。方法将雄性C57BL/6小鼠随机分为空白对照组和模型组,皮下注射MPTP联合腹腔注射丙磺舒（MPTP/p）,空白对照组以相同方法注射生理盐水,每4 d注射1次,共注射10次。苏木素-伊红染色（hematoxylin-eosin staining, HE）评估小鼠肝组织结构病理变化,免疫组化法观察肝脏组织不同形式α-突触核蛋白（α-synuclein, α-syn）的变化,以及8-羟基脱氧鸟苷（8-hydroxy-2 deoxyguanosine,8-OHdG）和4-羟基壬烯醛（4-hydroxy-2-nonenal, 4-HNE）表达改变。通过使用自由氧（reactive oxygen species, ROS）荧光探针— 二氢乙啶（dihydr-oethidium, DHE）染色检测肝脏部位的ROS水平。Western blot和免疫荧光检测肝组织内核转录相关因子2（Nuclear factor erythroid 2 related factor 2, Nrf2）在细胞核和细胞浆中的分布情况。结果 MPTP/p联合诱导的PD小鼠模型中,肝组织表现出明显的炎症反应;硝基化形式的α-syn（n-syn）和寡聚体形式的α-syn（5G4）蛋白含量明显增加;肝组织内发生了脱氧核糖核酸（DNA）损伤及氧化应激反应;肝组织中的Nrf2总蛋白表达上调,胞浆中的Nrf2显著减少。结论 PD致病相关因素能够诱导动物模型肝脏病理结构和生理功能发生显著变化,上述改变与氧化应激密切相关,α-syn可作为机体病变的指示分子。

关键词: 1-甲基-4-苯基-1,2,3,6-四氢吡啶, 帕金森病, 肝脏, α-突触核蛋白, 氧化应激

Abstract: Objective To investigate the physiological function and pathological changes of the liver in a mouse model of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) induced Parkinson's disease (PD). Methods Male C57BL/6 mice were randomly divided into the control group and model group. The model group received subcutaneous injection of MPTP combined with an intraperitoneal injection of probenecid (MPTP/p) every 4 days with MPTP/p for 10 times, while the control group was injected with physiological saline in the same way. The pathological changes of the mouse liver were assessed by Hematoxylineosin staining (HE), while the changes of different forms of α-synuclein (α-syn) in the liver, and those of expressions of 8-hydroxydeoxyguanosine (8-OHdG) and 4-hydroxy-2-Nonenal (4-HNE) were measured using an immunohistochemical method. The level of ROS in the liver was detected by dihydroethidium (DHE) staining with a fluorescent probe of reactive oxygen species (ROS). Western blot and immunofluorescence were used to detect the distribution of nuclear factor erythroid-2 related factor 2 (Nrf2) in the nucleus and cytoplasm of liver tissue. Results In the PD mouse model induced by MPTP/p, liver tissue showed obvious inflammatory infiltration. The levels of the nitrated form of α-syn (n-syn) and oligomeric form of α-syn (5G4) protein increased. DNA damage and oxidative stress occurred in liver tissue. The expression of total Nrf2 protein in liver cells was up-regulated, but Nrf2 in the cytoplasm was reduced significantly. Conclusion PD pathogenic factors can induce significant changes in the pathological structure and physiological functions of the liver in model animals. The above changes are closely related to oxidative stress, and α-syn can be used as an indicator molecule for body disease.

Key words: MPTP, Parkinson's disease, liver, α-synuclein, oxidative stress

中图分类号:

R994.1

韩奇文, 陈颖, 陈乃宏, 苑玉和. MPTP诱导小鼠肝脏帕金森病样病理变化研究[J]. 中国药物警戒, 2021, 18(4): 306-311.

HAN Qiwen, CHEN Ying, CHEN Naihong, YUAN Yuhe. Study on MPTP-induced Parkinson's Disease-like Pathological Changes in Mice Liver[J]. Chinese Journal of Pharmacovigilance, 2021, 18(4): 306-311.

参考文献

[1] Stochl J, Boomsma A, Ruzicka E, et al.On the structure of motor symptoms of Parkinson's disease[J]. Movement disorders : Official Journal of the Movement Disorder Society, 2008, 23(9): 1307-1312.
[2] Fayyad M, Salim S, Majbour N, et al.Parkinson's disease biomarkers based on α-synuclein[J]. Journal of Neurochemistry, 2019, 150(5): 626-636.
[3] Lian Y.Research progress of traditional Chinese medicine on Parkinson's disease with deficiency of liver and kidney[J]. Nei Mongol Journal of Traditional Chinese Medicine(内蒙古中医药), 2020, 39(6): 162-163.
[4] Gong ZB, Wu ZH.Mechanism of bushen pinggan xifeng decoction in improving the appearance and behavior of parkinson's ddisease model rats[J]. Journal of Hubei University of Chinese Medicine(湖北中医药大学学报), 2020, 22(3): 21-24.
[5] Li WL, Jin W, Chen BH, et al.One case of cellulitis induced by pramipexole hydrochloride tablets[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(4): 246-247, 251.
[6] Kalia LV, Lang AE.Parkinson's disease[J]. Lancet (London, England), 2015, 386(9996): 896-912.
[7] Seppi K, Ray Chaudhuri K, Coelho M, et al.Update on treatments for nonmotor symptoms of parkinson's disease-an evidence-based medicine review[J]. Movement disorders : Official Journal of the Movement Disorder Society, 2019, 34(2): 180-198.
[8] Zhu MH, Li YY, Zhao YL, et al.Changes of hepatic function and histopathology in mouse and monkey model of parkinson's disease[J]. Journal of Guangzhou University of Traditional Chinese Medicine(广州中医药大学学报), 2016, 33(2): 243-247.
[9] Langston JW, Ballard P, Tetrud JW, et al.Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis[J]. Science (New York, N.Y.), 1983, 219(4587): 979-980.
[10] Yao L, Dai X, Sun Y, et al.Inhibition of transcription factor SP1 produces neuroprotective effects through decreasing MAO b activity in MPTP/MPP Parkinson's disease models[J]. Journal of Neuroscience Research, 2018, 96(10): 1663-1676.
[11] Shao QH, Chen Y, Li FF, et al.TLR4 deficiency has a protective effect in the MPTP/probenecid mouse model of Parkinson's disease[J]. Acta Pharmacologica Sinica, 2019, 40(12): 1503-1512.
[12] Heng Y, Zhang QS, Mu Z, et al.Ginsenoside rg1 attenuates motor impairment and neuroinflammation in the MPTP-probenecid-induced parkinsonism mouse model by targeting α-synuclein abnormalities in the substantia nigra[J]. Toxicology Letters, 2016, 243: 7-21.
[13] Karpowicz RJ, Trojanowski JQ, Lee VMY.Transmission of α-synuclein seeds in neurodegenerative disease: recent develo- pments[J]. Laboratory Investigation, 2019, 99(7): 971-981.
[14] Kim S, Kwon SH, Kam TI, et al.Transneuronal propagation of pathologic α-synuclein from the gut to the brain models parkinson's disease[J]. Neuron, 2019, 103(4): 627-641.
[15] Dehay B, Bourdenx M, Gorry P, et al.Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations[J]. The Lancet. Neurology, 2015, 14(8): 855-866.
[16] Wojtovich AP, Berry BJ,Galkin A.Redox signaling through compartmentalization of reactive oxygen species: Implications for health and disease[J]. Antioxidants & Redox Signaling, 2019, 31(9): 591-593.
[17] Lee DH, Gold R, Linker RA.Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: therapeutic modulation via fumaric acid esters[J]. International Journal of Molecular Sciences, 2012, 13(9): 11783-11803.
[18] Yaribeygi H, Panahi Y, Javadi B, et al.The underlying role of oxidative stress in neurodegeneration: A mechanistic review[J]. CNS & Neurological Disorders Drug Targets, 2018, 17(3): 207-215.
[19] Puspita L, Chung S Y,Shim JW.Oxidative stress and cellular pathologies in Parkinson's disease[J]. Molecular Brain, 2017, 10(1): 53-53.
[20] Guo SS, Rausch WD.Study on neuroprotective effects of water extract of fomitopsis pinicola on dopaminergic neurons in vitro[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2018, 15(10): 582-586.
[21] Xia T, Zhang J, Yao JH, et al.Research progress in mechanism of oxidative stress in alcoholic liver disease[J]. Chinese Pharma cological Bulletin(中国药理学通报), 2017, 33(10): 1353-1356.
[22] Tu W, Wang H, Li S, et al.The anti-inflammatory and anti-oxidant mechanisms of the keap1/Nrf2/ARE Signaling Pathway in Chronic Diseases[J]. Aging and Disease, 2019, 10(3): 637-651.
[23] Xu JH, Huang YM, Ling W, et al.Wen dan decoction for hemorrhagic stroke and ischemic stroke[J]. Complementary Therapies in Medicine, 2015, 23(2): 298-308.
[24] Guo XC, Liang Y, Ji T, et al.Theoretical discussion and application of warming kidney and nourishing liver method in the treatment of Parkinson's disease[J]. Journal of Sichuan of Traditional Chinese Medicine(四川中医), 2020, 38(3): 20-22.